OMIC Singular Genomics Systems Inc: Prakiraan rega marang bathi
The forward P/E dynamics of Singular Genomics Systems (OMIC) demonstrate that the value has stabilized at 0.00. The issuer is implementing ESG standards by reducing manufacturing defects and toxic emissions. Innovative equipment also minimizes energy costs and reagent consumption during research. However, expansion is hindered by severe pricing pressure from industry leaders, which limits the commercial growth rate of its benchtop analysis systems.
Rincian metrik keuangan lan pasar Singular Genomics Corp (OMIC)
- kuotasi lan prakiraan analis:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Utang marang Ekuitas Singular Genomics Systems|OMIC - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Singular Genomics Systems|OMIC - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku Singular Genomics Systems, Inc.|OMIC - Tanggungan jangka dawa|Utang jangka cendhak perusahaan Singular Genomics|Likuiditas cepet singulargenomics.com
- indikator profitabilitas perusahaan lan kelipatan valuasi:
OMIC - Bathi perusahaan|Bathi sing dikarepake Singular Genomics Systems|OMIC - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Singular Genomics Systems Inc|OMIC - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Singular Genomics Systems, Inc.|OMIC - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham (EPS TTM) Singular Genomics|OMIC - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan singulargenomics.com|OMIC - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Singular Genomics Systems
Pambiji fundamental:Singular Genomics
To qualitatively assess an asset, it is essential for an investor to compare the current market share price with the projected annual net income, which allows them to determine the extent of the premium paid for future success via the company's forward P/E multiple. This indicator reflects market expectations regarding the scaling of Singular Genomics Systems (OMIC), where profit growth driven by regular shipments of DNA sequencing reagents must justify the high multiple.
Analisis pesaing
Pangali Forward P/E TEM|Qiagen NV (QGEN) - Pangali forward rega marang bathi|Ionis Pharma - Prakiraan rega marang bathi|Pangali Forward P/E Repligen Inc. RGEN|RNA - Rega marang bathi mangsa ngarep|CRSP: Rega marang bathi mangsa ngarep|WGS: Pangali Forward P/E|Ultragenyx Pharmaceutical Inc. (RARE) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Beam Therapeutics Corp|SRPT: Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi TWST (Twist Bioscience)|TXG (10xgenomics.com) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E NTLA (Intellia Therapeutics, Inc.)|Pangali forward rega marang bathi Stoke Therapeutics Inc|BioLife Corp - Pangali Forward P/E|Rasio prakiraan rega marang bathi Wave Pharma|Maze Therapeutics Inc (MAZE) - Rega marang bathi mangsa ngarep|Rasio rega marang bathi mangsa ngarep SION|Rega marang bathi mangsa ngarep Prime Medicine|Rasio prakiraan rega marang bathi Taysha Gene Therapies Inc TSHA|Rega marang bathi mangsa ngarep uniQure Corp (QURE)|Prakiraan rega marang bathi MeiraGTx Corp MGTX|Pangali Forward P/E RGNX (REGENXBIO Inc.)|Kapitalisasi marang proyeksi bathi solidbio.com (SLDB)|Ocugen - Pangali Forward P/E|Pacific Biosciences of California, Inc. (PACB) - Prakiraan rega marang bathi|Benitec (BNTC) - Rega marang bathi mangsa ngarep|DSGN - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi RCKT|FDMT: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Lexeo Therapeutics (LXEO)|Kapitalisasi marang proyeksi bathi korrobio.com|Editas - Prakiraan rega marang bathi|Silence Therapeutics Corp (SLN) - Rasio prakiraan rega marang bathi|PRQR - Rega marang bathi mangsa ngarep|Kapitalisasi marang proyeksi bathi Codexis, Inc. CDXS|SGMO (Sangamo Therapeutics, Inc.) - Prakiraan rega marang bathi|NAUT: Rasio kapitalisasi marang bathi mangsa ngarep|MGX (Metagenomi, Inc) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Precision BioSciences Inc. DTIL|Rega marang bathi mangsa ngarep Generation Bio Co. (GBIO)|Prakiraan rega marang bathi boundlessbio.com BOLD|Rega marang bathi mangsa ngarep Exicure XCUR|Kapitalisasi marang proyeksi bathi Imunon Inc (IMNN)|PHIO - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi Mustang Bio, Inc.|transcodetherapeutics.com (RNAZ) - Rega marang bathi mangsa ngarep|Prakiraan rega marang bathi Bionano Genomics|APDN (Applied DNA Sciences, Inc.) - Pangali Forward P/E|bluebird bio Inc. (BLUE) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E IPA|Prakiraan rega marang bathi Omega Therapeutics Corp OMGA|Pangali Forward P/E RGLS (Regulus Therapeutics)|SYRS: Rasio rega marang bathi mangsa ngarep|TBIO - Rega marang bathi mangsa ngarep|TCON (TRACON Pharmaceuticals Inc.) - Rasio rega marang bathi mangsa ngarep|UBX: Pangali Forward P/E
